Cancer

Microbix Presents Novel HSV Test Control at EMMD

Innovative QAP to Support Patient Diagnosis & Analysis of Infected Tissue SamplesMISSISSAUGA, Ontario, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Microbix…

1 year ago

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29

RAMAT GAN, Israel , Oct. 07, 2024 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company…

1 year ago

Terry Lynch Joins BioNxt as Capital Markets Advisor

VANCOUVER, BC / ACCESSWIRE / October 7, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased…

1 year ago

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in…

1 year ago

Bone Health and Osteoporosis Foundation (BHOF) Awarded Multi-Year Grant to Increase Bone Health Awareness from the Centers for Disease Control and Prevention (CDC)

ARLINGTON, Va., Oct. 4, 2024 /PRNewswire/ -- The Bone Health and Osteoporosis Foundation announced that it has been awarded a major…

1 year ago

CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial

VANCOUVER, Washington, Oct. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab,…

1 year ago

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

October 4, 2024 Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent…

1 year ago

Poseida Therapeutics Named to Newsweek’s List of the Top 200 America’s Most Loved Workplaces for 2024

Inclusion on list recognizes Poseida for employee sentiment and satisfaction SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq:…

1 year ago